| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 6, 2017
Introducing SmartCRT™ technology, providing MultiSite Pacing with up to 13.3 years battery life.i Boston Scientific Europe today announced the launch of the RESONATE™ cardiac resynchronisation...
-
Oct 13, 2016Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day.
A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in...
-
Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...
-
Jun 14, 2016Studies show that treatment is less costly and has lower hospital re-admissions
Boston Scientific Corporation (NYSE: BSX) today announced that its GreenLight XPS™ Laser Therapy System, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia...
-
May 19, 2016Final, 5-year results from the EVOLVE Trial evaluating the Boston Scientific (NYSE: BSX) SYNERGY Stent support long-term safety and efficacy for the treatment of patients with de novo coronary artery disease.
The final 5 year results of the EVOLVE Trial reinforce earlier findings of sustained performance of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System, with no stent thrombosis (ST), a...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 17, 2016Outcomes from this post market study of more than 1,000 patients demonstrate the safety and efficacy of transcatheter aortic valve implantation (TAVI) with the LOTUS™ Valve in routine clinical practice.
Results from the RESPOND Study evaluating the Boston Scientific (NYSE: BSX) LOTUS™ Valve demonstrated excellent outcomes of key safety and efficacy endpoints through 30 days post implant...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 13, 2016WATCHMAN™ LAAC Device EWOLUTION Real-World Outcomes to be Featured as Late Breaking Clinical Trial
Boston Scientific (NYSE: BSX) today announced its schedule of key data, that will be featured at the annual EuroPCR Scientific Program, May 17-20 in Paris. Data from the 1,000-patient EWOLUTION...
May 3, 2016To mark World Asthma Day, Boston Scientific continues with our commitment to raise awareness of the devastating impact severe asthma can have. Severe asthma isn’t just ‘really bad asthma’,...
-
May 2, 2016“Despite my disease, I want to set things in motion, starting with myself!”
On average about 48 kilometers – that is the distance that Tony Seidl will cycle every day during his eleven day tour from Altoetting, Germany to Padua, Italy. For most people this would already...
-
Apr 20, 2016European Approval Granted for Third-Generation System and All Previously Implanted, Second-Generation Systems
Boston Scientific (NYSE: BSX) has received CE Mark approval for the new EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling...
-
Apr 11, 2016
In recognition of James Parkinson's birthday, April 11th is celebrated globally as World Parkinson's Day. Parkinson’s disease (PD) is a chronic progressive neurological disorder which affects...
-
Feb 22, 2016First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and Asia
Boston Scientific (NYSE: BSX) today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received CE Mark and is commencing commercialization immediately in the European Union and...
Jan 12, 2016Single-Use System for stone removal eliminates maintenance, reprocessing and sterilizationBoston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVueTM Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...
-
Dec 11, 2015
Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provides more than 70 percent greater...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...
-
Sep 28, 2015A media briefing with a difference: join us for this interactive session on severe asthma. Hear from Europe’s leading experts in asthma and visit our information stations to bring the story to life.
September 28, 2015, 18:30 – 20:00 Wyndham Apollo Hotel Amsterdam (15 minutes from the ERS Congress Venue, the Amsterdam RAI Exhibition and Convention Centre) Agenda 18:30 Welcome and scene...
-
Sep 28, 2015Work, social and family life all affected by severe asthma, many people report feelings of anxiety, depression and isolation as well
Boston Scientific today revealed results of a comprehensive survey which shows the true burden of severe asthma and the daily challenges faced by people with asthma in Europe. Uncovering Asthma, a...
-
Sep 28, 2015MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...
-
Sep 26, 2015
Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...
-
Sep 10, 2015System includes first directional lead with current steering and expanded programming flexibility
Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
-
Aug 31, 2015
Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...
-
Aug 24, 2015
Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...
-
Aug 4, 2015
Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase the American Medical Systems (AMS)...
-
Jul 22, 2015
First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller Ventricles Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new...
-
Jun 23, 2015The new generation of subcutaneous defibrillators selected as most innovative in the field of cardiac electrophysiology.
MILAN, Italy, June 23, 2014 – Attendees of EHRA EUROPACE-CARDIOSTIM 2015, a global medical conference held recently in Milan, Italy, have selected the EMBLEM™ S-ICD System as the most...
-
Jun 22, 2015
Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...
-
Jun 10, 2015Please join us for a Boston Scientific press event. Protection from sudden cardiac death, just under the skin: the EMBLEM™ Subcutaneous ICD System
SAVE THE DATE: June 23, 2015. Milan, Italy. Enterprise Hotel Corso Sempione, 91-93 20149 Milan, Italy We would like to invite you to our press event on June 23, 2015 dedicated to an innovative,...
-
Jun 4, 2015
World’s Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord...
-
May 20, 2015
Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System...
-
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year.
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
-
Apr 28, 2015MAJESTIC Trial Meets Performance Endpoint With Compelling Results
In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System met...
-
Apr 27, 2015
Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and...
-
Mar 19, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Sep 29, 2014
New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Aug 30, 2014
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Jul 11, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman. DISCLAIMER: Please be...
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman.
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...